A Randomized, Double Blind, Placebo Controlled, Phase 2 Study to Assess the Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of LNP1892 (Monotherapy) in Chronic Kidney Disease (CKD) Patients with Secondary Hyperparathyroidism (SHPT), On Dialysis and Not on Dialysis
Latest Information Update: 04 Jul 2019
At a glance
- Drugs LNP 1892 (Primary)
- Indications Secondary hyperparathyroidism
- Focus Therapeutic Use
- Sponsors Lupin
- 17 Jun 2019 Status changed from recruiting to completed.
- 13 Dec 2017 New trial record